Morgan Stanley Sticks to Its Buy Rating for BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.
WESA14h
Penn expecting $467M windfall from COVID-19 vaccine royalty dispute
The university filed a lawsuit against BioNTech four months ago, claiming that the company licensed vaccine technology ...
BUCKSCO.Today on MSN2d
BioNTech Agrees to Pay $467M to Penn as Part of COVID-19 Vaccine Royalties Settlement
University of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine royalties, writes John George ...
FiercePharma3d
BioNTech inks settlements with NIH, Penn in COVID-19 vaccine royalty disputes
The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...
BioPharma Dive4d
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...
Billy Penn6d
BP ’24 year in review: Support Billy Penn in 2025; A record warm year | Morning roundup
In Review 805 articles and counting2,837 new Instagram followers1,771 new Bluesky followers It was quite a year. Join us in ...
Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after new settlement
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley
Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the National Institutes of Health and University of Pennsylvania ...